Drugs / anti-CD33 CAR NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05008575 | Dec 2021 → Dec 2022 | acute myeloid leukemia | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02944162 | Oct 2016 → Sep 2017 | acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD33 CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02944162 ↗ |
| Known as | Chimeric antigen receptor NK92 cells with specificity for CD33 | “Chimeric antigen receptor NK92 cells with specificity for CD33” NCT02944162 ↗ |
| Action | Deplete | “determine leukemia cell killing by anti-CD33 CAR-NK in vitro.” NCT02944162 ↗ |
| Modality | Cell therapy | “The purpose of this clinical trial is to study genetically engineered NK92 cell therapy” NCT02944162 ↗ |
| Target | CD33 | “These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.” NCT02944162 ↗ |